In contrast, we could not detect any significant change in gene expression of neither receptors Tyro3
and Mertk (Figures 1(a) and 1(c)) nor ligands Gas6 and Pros1 (Figures 1(d) and 1(e)) as compared to controls.
AXL receptor which belongs to the TYRO3
AXL MER (TAM) family, a group of tyrosine kinase receptors involved in the clearance of apoptotic cells and regulation of innate immunity [15, 16], is the best described target of Flavivirus.
Growth arrest-specific (Gas) 6 structurally belongs to the family of plasma vitamin K-dependent proteins and has growth factor-like properties through its interaction with receptor tyrosine kinases of the TAM family; Tyro3
, Axl, and Mertk [9, 10].
Under the terms of the agreement, Celldex acquires the multi-faceted TAM programme, which is a broad antibody discovery effort underway to generate antibodies that modulate the TAM family of RTKs, comprised of Tyro3
, AXL and MerTK, which are expressed on tumor-infiltrating macrophages, dendritic cells and some tumors across immuno-oncology and inflammatory diseases.
Mer tyrosine kinase (MerTK) is an integral membrane protein that is preferentially expressed in hematopoietic lineages such as monocytes/macrophages, dendritic cells (DCs), and natural killer (NK) cells [1, 2], which is one of the three members of TAM (Tyro3
, Axl, Mer) family receptor tyrosine kinases [3, 4].
- The US Food and Drug Administration has cleared San Diego, California-based oncology therapeutics developer Ignyta, Inc.'s (NASDAQ: RXDX) investigational new drug application (IND) for RXDX-106, a novel oral immunomodulatory agent and TYRO3
, AXL, and MER (collectively, TAM) inhibitor, in patients with solid tumors, the company said.
Tam receptor kinases (Tyro3
, Axl, Mer) present on apoptotic cell membranes inhibit TLR and cytokine-induced signaling cascades, therefore preventing immunogenicity of the autoantigens presented .
Lai, "Localization and signaling of the receptor protein tyrosine kinase Tyro3
in cortical and hippocampal neurons," Neuroscience, vol.
Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases, including TAM family receptors (TYRO3
, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
RXDX-106 modulates the tumor microenvironment (TME) through TYRO3
, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition.